Haemonetics reports Q3 adjusted EPS 85c, consensus 80c
The Fly

Haemonetics reports Q3 adjusted EPS 85c, consensus 80c

Reports Q3 revenue $305.3M, consensus $300.47M. Chris Simon, Haemonetics’ CEO, stated: "Our strong performance continued in the third quarter despite the challenging macroeconomic environment. We are fueling our momentum and using it to invest in our Long-Range Plan, expanding our capital capacity and creating new opportunities to accelerate transformational growth and margin expansion."

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on HAE:

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App